OcuMension Therapeutics
Company which focuses on the development of ophthalmic medications.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | Post IPO Equity | |
| Total Funding | 000k | ||
| CNY | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 329 % | 183 % | 55 % | 69 % | 100 % | 43 % | 30 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (661 %) | (224 %) | (132 %) | (42 %) | 10 % | 21 % | 33 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (463 %) | (253 %) | (154 %) | (64 %) | (12 %) | 5 % | 9 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 301 % | 116 % | 50 % | 27 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Ocumension Therapeutics specializes in developing and commercializing innovative ophthalmic solutions aimed at enhancing eye health. The company operates in the pharmaceutical sector, focusing on the treatment of eye diseases and conditions. Ocumension serves a diverse range of clients, including healthcare providers, hospitals, and clinics, primarily in the Asia-Pacific region. The business model revolves around research and development, clinical trials, and the subsequent commercialization of its products. Revenue is generated through the sale of its therapeutic products and potential licensing agreements with other pharmaceutical companies.
Keywords: ophthalmic solutions, eye health, therapeutics, pharmaceutical, Asia-Pacific, healthcare providers, hospitals, clinics, research and development, commercialization.
Tech stack
Investments by OcuMension Therapeutics
Edit
